Get the Stockscreener App
20.27
0.15%
-0.03
Pre-market:
19.41
-0.86
-4.24%
Enliven Therapeutics Inc stock is traded at $20.27, with a volume of 452.66K.
It is down -0.15% in the last 24 hours and down -1.98% over the past month.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
See More
Previous Close:
$20.30
Open:
$20.31
24h Volume:
452.66K
Relative Volume:
0.86
Market Cap:
$1.20B
Revenue:
-
Net Income/Loss:
$-85.21M
P/E Ratio:
-10.72
EPS:
-1.89
Net Cash Flow:
$-68.53M
1W Performance:
+10.77%
1M Performance:
-1.98%
6M Performance:
+1.20%
1Y Performance:
-21.43%
1-Day Range:
$19.93
$21.57
1-Week Range:
$16.80
$21.57
52-Week Range:
$13.30
$27.20
Enliven Therapeutics Inc Stock (ELVN) Company Profile
Name
Enliven Therapeutics Inc
Sector
Industry
Phone
720-647-8519
Address
6200 LOOKOUT ROAD, BOULDER
Compare ELVN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ELVN
Enliven Therapeutics Inc
|
20.27 | 1.20B | 0 | -85.21M | -68.53M | -1.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.16B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
694.99 | 71.65B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.97 | 59.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
891.73 | 54.79B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
368.36 | 41.77B | 4.98B | 69.59M | 525.67M | 0.5197 |
Enliven Therapeutics Inc Stock (ELVN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-16-25 | Initiated | Goldman | Buy |
| Dec-13-24 | Initiated | BTIG Research | Buy |
| Sep-09-24 | Initiated | H.C. Wainwright | Buy |
| Jun-11-24 | Initiated | Robert W. Baird | Outperform |
| Apr-09-24 | Initiated | Mizuho | Buy |
| Mar-29-23 | Initiated | Jefferies | Buy |
View All
Enliven Therapeutics Inc Stock (ELVN) Latest News
What analyst consensus says on Enliven Therapeutics Inc. stock2025 Institutional Moves & Growth Focused Investment Plans - newser.com
Is Enliven Therapeutics Inc. stock a contrarian buyJuly 2025 Weekly Recap & Reliable Volume Spike Trade Alerts - newser.com
Enliven Therapeutics Inc. stock daily chart insights2025 Momentum Check & Free Community Supported Trade Ideas - newser.com
Decoding Enliven Therapeutics Inc (ELVN): A Strategic SWOT Insig - GuruFocus
Enliven Therapeutics Reports Q3 2025 Financial Results - TipRanks
Published on: 2025-11-12 22:06:18 - newser.com
Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update - PR Newswire
Published on: 2025-11-12 18:07:48 - newser.com
Enliven Therapeutics Keeps Moving Forward As Losses Narrow And Cash Holds Strong - Finimize
Enliven Therapeutics Q3 net loss narrows - MarketScreener
Enliven Therapeutics Inc Stock Analysis and ForecastDay Trading Setups & Budget Friendly Growth - earlytimes.in
Published on: 2025-11-11 21:28:07 - newser.com
Enliven Therapeutics Advances Precision Oncology Research - Kalkine Media
Enliven Therapeutics (ELVN) Projected to Post Earnings on Wednesday - Defense World
Will ELVN-001 Enable Enliven Therapeutics To Capture A Share Of The CML Market? - RTTNews
Published on: 2025-11-10 05:45:09 - newser.com
Real time breakdown of Enliven Therapeutics Inc. stock performanceJuly 2025 Selloffs & Smart Investment Allocation Insights - newser.com
Using data filters to optimize entry into Enliven Therapeutics Inc.Breakout Watch & Daily Stock Trend Watchlist - newser.com
Will Enliven Therapeutics Inc. stock continue dividend increasesJuly 2025 Drop Watch & Weekly Momentum Picks - Fundação Cultural do Pará
Can Enliven Therapeutics Inc. stock deliver strong Q4 earningsJobs Report & Free AI Powered Buy and Sell Recommendations - newser.com
Is Enliven Therapeutics Inc. stock attractive for retirement portfoliosMarket Performance Summary & Real-Time Chart Pattern Alerts - fcp.pa.gov.br
Head-To-Head Comparison: Enliven Therapeutics (NASDAQ:ELVN) vs. NLS Pharmaceutics (NASDAQ:NCEL) - Defense World
Is Enliven Therapeutics Inc. stock positioned well for digital economyQuarterly Profit Review & Technical Pattern Recognition Alerts - newser.com
Enliven Therapeutics, Inc. (ELVN) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
Published on: 2025-11-05 22:17:31 - newser.com
Is Enliven Therapeutics Inc. stock cheap compared to fundamentalsDollar Strength & Consistent Growth Equity Picks - newser.com
Published on: 2025-11-05 21:38:45 - newser.com
Enliven Therapeutics Inc. recovery potential after sell offJuly 2025 Big Picture & AI Optimized Trade Strategies - newser.com
(ELVN) Price Dynamics and Execution-Aware Positioning - news.stocktradersdaily.com
Stocks of Enliven Therapeutics Inc (ELVN) are poised to climb above their peers - setenews.com
Enliven Therapeutics (NASDAQ:ELVN) Stock Price Down 12.3%Here's What Happened - MarketBeat
Is Enliven Therapeutics Inc. stock a buy for dividend growthQuarterly Portfolio Summary & Long-Term Growth Plans - Fundação Cultural do Pará
Fed Watch: Is Enliven Therapeutics Inc. stock positioned well for digital economyQuarterly Portfolio Review & Risk Managed Investment Entry Signals - Fundação Cultural do Pará
Enliven Therapeutics showcases promising results for ELVN-001 in CML trial - Traders Union
Enliven (NASDAQ: ELVN) presents ELVN-001 CML data at ASH 2025 with >1 log transcript declines - Stock Titan
Enliven Therapeutics Inc Stock (ELVN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.35%
0.75%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):